Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sejuti Banerjea headshot

Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood

by Sejuti Banerjea

JNJ Management expects relatively consistent growth for the rest of the year.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Strong Invisalign adoption and continued growth in the iTero scanner installed base are likely to have driven Align Technology's (ALGN) Q2 performance.

Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada

by Zacks Equity Research

Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.

AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine

by Zacks Equity Research

AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.

Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?

by Zacks Equity Research

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.

Merck and Block have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Merck and Block have been highlighted as Zacks Bull and Bear of the Day.

Benjamin Rains headshot

Bull of the Day: Merck & Co. (MRK)

by Benjamin Rains

Merck & Co. (MRK) is a $240 billion market cap pharmaceutical titan that's climbed over 20% in 2022. The firm is continuing to make acquisitions and many of Merck's fundamentals make it an attractive play for the second half of 2022

UnitedHealth Group (UNH) Q2 Earnings Beat, Hikes '22 EPS View

by Zacks Equity Research

UnitedHealth Group's (UNH) second-quarter results gain from revenue growth stemming from solid segmental contributions and membership growth. A raised 2022 EPS view remains noteworthy.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.

Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M

by Zacks Equity Research

Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.

J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued in the second.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds

by Kinjel Shah

Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.

Best Growth Stocks to Buy for July 15th

by Zacks Equity Research

: DLTR, LNTH and MRK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 15, 2022.

Best Income Stocks to Buy for July 15th

by Zacks Equity Research

IBCP, PBR, and MRK made it to the Zacks Rank #1 (Strong Buy) income stocks list on July 15, 2022.

Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study

by Zacks Equity Research

Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.

Here's Why Investors Should Retain Phibro (PAHC) For Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) major animal health products and robust vaccine sales.

LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis

by Zacks Equity Research

LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.

Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate

by Zacks Equity Research

Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.

What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?

by Zacks Equity Research

Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q2 on the continuous rollout of Alinity.

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $93.77, marking a +0.18% move from the previous day.

Here's Why You Should Retain Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) strong end market growth and noteworthy acquisitions.

Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) reports favorable data from a mid-stage study evaluating the efficacy of setmelanotide, its MC4R agonist, for treating hypothalamic obesity.

Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?

by Zacks Equity Research

Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.

Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study

by Zacks Equity Research

Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.

CVS Health (CVS) Pharmacy Claims Volume Grows, Margin Woes Stay

by Zacks Equity Research

CVS Health's (CVS) investments in constructing affordable housing units in Denver, Fresno, Nashville and San Antonio seem encouraging.